Scribd Logo
Upload

Welcome to Scribd!

  • Politics: Cardio3 Moves Into CAR T-Cell Therapies: European Biotechnology News

    Uploaded by

    vijender
    15 views3 pages
    Cardio3 Biosciences acquired Celdara Medical's cancer division, moving into CAR T-cell cancer therapies. The EMA is seeking input on implementing transparency rules for clinical trial data from the new EU Clinical Trial Regulation. Shire acquired NPS Pharma for $5.2 billion to expand its rare disease portfolio. Valneva bought the oral cholera vaccine Dukoral to strengthen its vaccine business. Novartis made two deals involving the CRISPR genome editing technology. The EU will provide €215 million to fund Ebola vaccine projects through its IMI2 Ebola+ program.

    Original Description:

    bio;

    Original Title

    Bio;

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Cardio3 Biosciences acquired Celdara Medical's cancer division, moving into CAR T-cell cancer therapies. The EMA is seeking input on implementing transparency rules for clinical trial data from the new EU Clinical Trial Regulation. Shire acquired NPS Pharma for $5.2 billion to expand its rare disease portfolio. Valneva bought the oral cholera vaccine Dukoral to strengthen its vaccine business. Novartis made two deals involving the CRISPR genome editing technology. The EU will provide €215 million to fund Ebola vaccine projects through its IMI2 Ebola+ program.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as docx, pdf, or txt
    15 views3 pages

    Politics: Cardio3 Moves Into CAR T-Cell Therapies: European Biotechnology News

    Uploaded by

    vijender
    Cardio3 Biosciences acquired Celdara Medical's cancer division, moving into CAR T-cell cancer therapies. The EMA is seeking input on implementing transparency rules for clinical trial data from the new EU Clinical Trial Regulation. Shire acquired NPS Pharma for $5.2 billion to expand its rare disease portfolio. Valneva bought the oral cholera vaccine Dukoral to strengthen its vaccine business. Novartis made two deals involving the CRISPR genome editing technology. The EU will provide €215 million to fund Ebola vaccine projects through its IMI2 Ebola+ program.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as docx, pdf, or txt
    of 3

    1.

    Politics: Cardio3 moves into CAR T-cell therapies


    European Biotechnology News-08-Jan-2015
    08.01.2015 - Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with
    the acquisition of Celdara Medical's cancer division ...

    2. Regulation: EMA seeks trial data transparency input


    European Biotechnology News-22-Jan-2015
    21.01.2015 - The EMA is asking for comments on how to implement the transparency rules of EU Clinical
    Trial Regulation, pointing to the new clinical trial portal ...

    3.
    M&A: Champers for Shire as it bags NPS Pharma
    European Biotechnology News-13-Jan-2015
    13.01.2015 - Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of
    becoming a leading biotech in a US$5.2bn deal. Part of the ...
    Shire in $5.2bn deal for US biotech NPS
    Irish Times-11-Jan-2015
    Explore in depth (372 more articles)

    4.
    Business: Valneva buys cholera vaccine
    European Biotechnology News-06-Jan-2015
    05.01.2015 - Austrian-French biotech company Valneva SE is bolstering its vaccine business and has
    acquired oral cholera vaccine Dukoral and its ...

    5.
    M&A: Double CRISPR deals for Novartis
    European Biotechnology News-09-Jan-2015
    09.01.2015 - The excitement surrounding CRISPR genome editing shows no sign of abating. This month,
    Novartis and US biotech Intellia Therapeutics became ...

    6.

    Research: IMI funds Ebola vaccine projects


    European Biotechnology News-20-Jan-2015
    20.01.2015 - Ebola research projects are set to receive 215m in funding from the European
    Commission's IMI2 Ebola+ programme. Among the project partners ...

    7. After Disney Measles Outbreak, Immunityland Less Magical


    Genetic Engineering & Biotechnology News-26-Jan-2015
    Take a hard line. Demand that we restrict the philosophical/religious exemptions to immunization. Raise
    the possibility of imposing sanctions on recalcitrant ...

    8.
    Columbia University Medical Center forges $30 million alliance with ...
    CU Columbia Spectator-16 hours ago
    Columbia University Medical Center and Biogen Idec, a globalbiotechnology company, have entered
    into a $30 million alliance that will result ...

    9.
    Biogen forecasts 2015 earnings well ahead of Street view
    Reuters-6 hours ago
    The biotechnology company posted a net profit of $883 million, or $3.74 per share, compared with a
    profit of $457.3 million, or $1.92 per share, ...
    Biogen Idec to add 100 jobs in RTP
    Triangle Business Journal-6 hours ago
    Explore in depth (53 more articles)

    10.
    Huffington Post (blog)

    Poll: Scientists overwhelmingly think GMOs are safe to eat. The ...
    Vox-7 hours ago
    ... by the modern molecular techniques of biotechnology is safe." The European Commission agreed,
    after sifting through 25 years of research.
    AAAS Scientists: Consensus on GMO Safety Firmer Than For ...
    Huffington Post (blog)-8 hours ago
    Explore in depth (153 more articles)

    Stay up to date on results for biotechnology news.


    Create alert

    10

    Next

    The selection and placement of stories on this page were determined automatically by a computer programme. The time or date displayed
    reflects when an article was added to or updated in Google News.

    You might also like